DV
Dividend Vision

CTNM — Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

Total return is -11.3% over the past 2.4 years, 66.7 points behind SPY at 55.4%. Its deepest 1-year drawdown was 29.8%.

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapies for neuroscience, inflammation, and immunology indications. The company's lead asset, PIPE-791, is a brain-penetrant inhibitor in development for idiopathic pulmonary fibrosis and chronic pain, while PIPE-307 targets depression and relapse-remitting multiple sclerosis. The company does not currently distribute dividends and, as an early-stage biotech firm, may appeal primarily to investors with higher risk tolerance seeking potential long-term capital appreciation rather than current income.

CTNM key facts

Asset type
Stock
Asset class
Equity
Inception date
04/04/2024
Last close
$14.19
Market cap
$532,008,128
Average volume
747300.0
Beta
0.703
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.94